Clinical Trials Logo

Clinical Trial Summary

Background:

- Currently, National Cancer Institute treatment trials use clinical staff reporting to monitor adverse side effects. The clinical staff reports draw on items from the Common Terminology Criteria for Adverse Events (CTCAE).

- Several of the items in the CTCAE can be adapted for use in patient self-reporting of side effects. Researchers are interested in developing a patient-reported outcome (PRO) approach to the CTCAE.

Objectives:

- To develop questions that can be used to create a patient-reported outcome version of the CTCAE (PRO-CTCAE).

- To evaluate patient comprehension of and test the usefulness of the PRO-CTCAE questions among diverse groups of patients.

Eligibility:

- Individuals 18 years of age and older who are receiving chemotherapy or radiotherapy as cancer treatment.

- Participants must be able to speak and understand English.

Design:

- Researchers will conduct up to three rounds of interviews with patients currently receiving chemotherapy or radiation therapy treatments for cancer.

- Participants will be recruited independently from four different clinical treatment sites. At least 25 percent of patients will have an educational attainment of high school or less.

- Each patient will complete a two-part protocol, including a set of PROs that will be followed by a series of questions to evaluate patient comprehension, memory, perceived clarity, and judgment of the PROs.

- The research will be completed in approximately 1 hour, and participants will receive a small amount of compensation for their time and participation.


Clinical Trial Description

Background:

The current approach to monitoring adverse symptom events in NCI-sponsored treatment trials is clinical staff reporting, using items from the Common Terminology Criteria for Averse Events (CTCAE). Of the 1,059 discrete items in the CTCAE, approximately 77 contain a subjective component sufficient enough to be amenable to patient self-reporting such as pain, fatigue, nausea,

and hair loss. There is general agreement that the patient, via a self-report, is the best source for reporting symptoms. Studies have shown that when compared to clinician reports, patients report earlier onset, greater severity, and longer duration of symptoms.

In September 2008, the NCI awarded a contract (N02-PC-85002-29; PI: Basch; Co-I: Hay) to support the development of an electronic-based and psychometrically robust patient-reported outcomes version of the symptom-related AEs listed in the CTCAE in an effort to improve the accuracy and precision of grading of this class of AEs. To achieve this goal, we will conduct cognitive interviews with 77 newly-developed PRO items that will subsequently be subjected to psychometric analysis, usability testing, and feasibility testing in a range of treatment settings among diverse groups of patients.

Objectives:

The overall goal of this proposed study is to evaluate patient comprehension of 77 newly developed PRO items in a range of treatment settings among diverse groups of cancer patients. The objectives are to evaluate: 1) patients understanding of the language and 2) the usability of the technology interface for collecting the PRO data of the PRO-CTCAE system.

Eligibility:

Patients will be eligible for the study if they are 1) aged 18 or older; 2) English-fluent; 3) undergoing chemotherapy and/or radiotherapy with curative or palliative intent; and 4) can provide informed consent.

Design:

We will conduct up to three rounds of cognitive interviews in 100 cancer patients at participating cancer centers including MSKCC, Dana Farber Cancer Institute, Duke and M.D. Anderson. After completion of the first round of interviews, results will be analyzed for problematic items. Revised items will be reviewed in subsequent rounds as needed. The final PRO-CTCAE items will proceed to usability testing. Usability testing will comprise three main components: 1) observation of users interacting with the web-based assessment system coupled with think aloud protocols and extensive field notes; 2) user feedback using semi-structured interviews and short surveys; and 3) web analytics including tracking for different web pages, with clickstream analysis. Usability testing will be conducted with 60 clinical research staff and 60 patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01031641
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase
Start date November 19, 2009
Completion date July 16, 2020

See also
  Status Clinical Trial Phase
Completed NCT01359982 - Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects Phase 1
Completed NCT02140736 - Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
Completed NCT00947739 - Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma Phase 1
Completed NCT00725634 - A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma Phase 1
Completed NCT00222443 - Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy Phase 1
Recruiting NCT02211755 - Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors Phase 1
Completed NCT02048488 - A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Recruiting NCT06148220 - A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors N/A
Withdrawn NCT02786485 - Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Phase 1
Completed NCT01387841 - Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting Phase 2
Completed NCT00396864 - Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma Phase 1
Terminated NCT00023166 - Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas Phase 1
Recruiting NCT04417803 - Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques N/A
Recruiting NCT05775406 - Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Phase 1
Recruiting NCT02274584 - CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) Phase 1/Phase 2
Recruiting NCT01836822 - Bronchoscopic Sampling Techniques in Sarcoidosis N/A
Completed NCT02902237 - tTF-NGR Phase I Study Phase 1
Completed NCT02578316 - A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies. Phase 1
Recruiting NCT00900198 - Collection of Tissue Samples for Cancer Research
Completed NCT02740270 - Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas Phase 1